SEC Form 4 · accession 0001636282-26-000087
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sheldon Sloan
Officer — Chief Medical Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 9:33 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 1, 2026 | M | 8,334 | $27.46 | A | 8,334 | D | |
| Common StockF2 | Jul 1, 2026 | S | 6,500 | $87.52 | D | 1,834 | D | |
| Common StockF3 | Jul 1, 2026 | S | 1,834 | $88.34 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $27.46 | Jul 1, 2026 | M | 8,334 | D | — | Oct 1, 2034 | Common Stock | 8,334 | 305,000 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.